Drug intelligence / Profile preview

68Ga-C1

Development stage: Phase 1
Lead developer: Peking University First Hospital
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

68Ga-C1 is a Carbonic Anhydrase IX (CAIX) specific small molecule probe labeled with Gallium-68 (68Ga), designed for use in Positron Emission Tomography/Computed Tomography (PET/CT) imaging. It is being developed to evaluate its diagnostic value in clear cell renal cell carcinoma (ccRCC) patients, where CAIX is highly expressed. The probe aims to provide high-contrast imaging for precise diagnosis of ccRCC and is also being assessed for its safety, tolerability, and radiation dosimetry.

Other names: [68Ga]Ga-C1Gallium-68 C1Gallium68 C1Gallium 68 C1

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 68Ga-C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-C1.

Explore the full profile